Indanones as high-potency reversible inhibitors of monoamine oxidase

ChemMedChem

Volumn 10, Issue 5, 2015, Pages 862-873

  Mostert, Samantha ^a   Petzer, Anél ^a   Petzer, Jacobus P ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

indanones; inhibitors; molecular modeling; monoamine oxidase; parkinson's disease

Indexed keywords

5 ( 2 CYCLOHEXYLETHOXY) 2,3 DIHYDRO 1H INDEN 1 ONE; 5 ( 2 PHENOXYETHOXY) 2,3 DIHYDRO 1H INDEN 1 ONE; 5 ( 3 BROMOBENZYLOXY) 2,3 DIHYDRO 1H INDEN 1 ONE; 5 ( 3 CHLOROBENZYLOXY) 2,3 DIHYDRO 1H INDEN 1 ONE; 5 ( 3 PHENYLPROPOXY) 2,3 DIHYDRO 1H INDEN 1 ONE; 5 ( 4 BROMOBENZYLOXY) 2,3 DIHYDRO 1H INDEN 1 ONE; 5 ( 4 CHLOROBENZYLOXY) 2,3 DIHYDRO 1H INDEN 1 ONE; 5 (CYCLOHEXYLMETHOXY) 2,3 DIHYDRO 1H INDEN 1 ONE; 5 BENZYLOXY 2,3 DIHYDRO 1H INDEN 1 ONE; 5 [ 2 ( 4 BROMOPHENOXY)ETHOXY] 2,3 DIHYDRO 1H INDEN 1 ONE; 5 [ 2 ( 4 CHLOROPHENOXY)ETHOXY] 2,3 DIHYDRO 1H INDEN 1 ONE; 5 [( 4 METHYLPENTYL)OXY] 2,3 DIHYDRO 1H INDEN 1 ONE; 6 ( 2 CYCLOHEXYLETHOXY) 2,3 DIHYDRO 1H INDEN 1 ONE; 6 ( 3 BROMOBENZYLOXY) 2,3 DIHYDRO 1H INDEN 1 ONE; 6 ( 3 CHLOROBENZYLOXY) 2,3 DIHYDRO 1H INDEN 1 ONE; 6 ( 4 BROMOBENZYLOXY) 2,3 DIHYDRO 1H INDEN 1 ONE; 6 ( 4 CHLOROBENZYLOXY) 2,3 DIHYDRO 1H INDEN 1 ONE; 6 (BENZYLOXY) 2,3 DIHYDRO 1H INDEN 1 ONE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; INDAN DERIVATIVE; INDANONE DERIVATIVE; LAZABEMIDE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; OXIDOREDUCTASE INHIBITOR; PARGYLINE; TOLOXATONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; AMINE OXIDASE (FLAVIN CONTAINING); MONOAMINE OXIDASE A, HUMAN; RECOMBINANT PROTEIN;

ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVITY; IC50; MOLECULAR DOCKING; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; HUMAN; METABOLISM; SYNTHESIS;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84928489545     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201500059     Document Type: Article

References (38)

1. R. R. Ramsay, Curr. Top. Med. Chem. 2012, 12, 2189-2209.
2. R. R. Ramsay, Curr. Pharm. Des. 2013, 19, 2529-2539.
3. J. C. Shih, K. Chen, M. J. Ridd, Annu. Rev. Neurosci. 1999, 22, 197-217.
4. M. B. Youdim, D. Edmondson, K. F. Tipton, Nat. Rev. Neurosci. 2006, 7, 295-309.
5. M. B. Youdim, Y. S. Bakhle, Br. J. Pharmacol. 2006, 147, S 287 -S 296.
6. J. P. Finberg, Pharmacol. Ther. 2014, 143, 133-152.
7. T. L. Schwartz, CNS Spectr. 2013, 18, 25-32.
8. C. T. Lum, S. M. Stahl, CNS Spectr. 2012, 17, 107-120.
9. S. N. Deftereos, E. Dodou, C. Andronis, A. Persidis, Expert Rev. Clin. Pharmacol. 2012, 5, 413-425.
10. H. H. Fernandez, J. J. Chen, Pharmacotherapy 2007, 27, 174S-185S.
11. J. P. Finberg, J. Wang, K. Bankiewicz, J. Harvey-White, I. J. Kopin, D. S. Goldstein, J. Neural Transm. Suppl. 1998, 52, 279-285.
12. I. Berlin, H. J. Aubin, A. M. Pedarriosse, A. Rames, S. Lancrenon, G. Lagrue, Addiction 2002, 97, 1347-1354.
13. D. E. Edmondson, Curr. Pharm. Des. 2014, 20, 155-160.
14. J. S. Fowler, N. D. Volkow, G. J. Wang, J. Logan, N. Pappas, C. Shea, R. MacGregor, Neurobiol. Aging 1997, 18, 431-435.
15. N. Kaludercic, J. Mialet-Perez, N. Paolocci, A. Parini, F. Di Lisa, J. Mol. Cell. Cardiol. 2014, 73, 34-42.
16. M. Da Prada, G. Zürcher, I. Wüthrich, W. E. Haefely, J. Neural Transm. 1988, 26, 31-56.
17. U. Bonnet, CNS Drug Rev. 2003, 9, 97-140.
18. J. C. Provost, C. Funck-Brentano, V. Rovei, J. DEstanque, D. Ego, P. Jaillon, Clin. Pharmacol. Ther. 1992, 52, 384-393.
19. L. J. Legoabe, A. Petzer, J. P. Petzer, Bioorg. Med. Chem. Lett. 2014, 24, 2758-2763.
20. C. Binda, F. Hubálek, M. Li, Y. Herzig, J. Sterling, D. E. Edmondson, A. Mattevi, J. Med. Chem. 2005, 48, 8148-8154.
21. J. Reniers, C. Meinguet, L. Moineaux, B. Masereel, S. P. Vincent, R. Frederick, J. Wouters, Eur. J. Med. Chem. 2011, 46, 6104-6111.
22. L. Novaroli, M. Reist, E. Favre, A. Carotti, M. Catto, P. A. Carrupt, Bioorg. Med. Chem. 2005, 13, 6212-6217.
23. A. Petzer, A. Pienaar, J. P. Petzer, Drug Res. 2013, 63, 462-467.
24. A. Petzer, A. Pienaar, J. P. Petzer, Life Sci. 2013, 93, 283-287.
25. M. J. Krueger, F. Mazouz, R. R. Ramsay, R. Milcent, T. P. Singer, Biochem. Biophys. Res. Commun. 1995, 206, 556-562.
26. F. Mazouz, S. Gueddari, C. Burstein, D. Mansuy, R. Milcent, J. Med. Chem. 1993, 36, 1157-1167.
27. R. R. Ramsay, A. Olivieri, A. Holt, J. Neural Transm. 2011, 118, 1003-1019.
28. S. Y. Son, J. Ma, Y. Kondou, M. Yoshimura, E. Yamashita, T. Tsukihara, Proc. Natl. Acad. Sci. USA 2008, 105, 5739-5744.
29. C. Binda, J. Wang, L. Pisani, C. Caccia, A. Carotti, P. Salvati, D. E. Edmondson, A. Mattevi, J. Med. Chem. 2007, 50, 5848-5852.
30. Accelrys Discovery Studio ver. 3.1, Accelrys Software Inc., San Diego, CA (USA), 2005.
31. L. J. Legoabe, A. Petzer, J. P. Petzer, Eur. J. Med. Chem. 2012, 49, 343-353.
32. F. Hubálek, C. Binda, A. Khalil, M. Li, A. Mattevi, N. Castagnoli, D. E. Edmondson, J. Biol. Chem. 2005, 280, 15761-15766.
33. F. H. Costa, A. L. Rosso, H. Maultasch, D. H. Nicaretta, M. B. Vincent, Arq. Neuro-Psiquiatr. 2012, 70, 617-620.
34. C. U. Pae, J. A. Bodkin, K. B. Portland, M. E. Thase, A. A. Patkar, J. Clin. Psychiatry 2012, 73, 661-668.
35. B. Strydom, S. F. Malan, N. Castagnoli, Jr., J. J. Bergh, J. P. Petzer, Bioorg. Med. Chem. 2010, 18, 1018-1028.
36. B. Strydom, J. J. Bergh, J. P. Petzer, Arzneim.-Forsch. 2012, 62, 513-518.
37. A. Petzer, B. H. Harvey, G. Wegener, J. P. Petzer, Toxicol. Appl. Pharmacol. 2012, 258, 403-409.
38. W. L. DeLano, The PyMOL Molecular Graphics System, DeLano Scientific, San Carlos, CA, (USA), 2002.